Spinal arthrodesis is a major element of the spinal surgeon's practice. To attain successful fusion rates, attention must be paid to spinal segment immobilization and proper selection of bone graft. Autogenous bone graft (ie, ICBG), the "gold standard, " with or without graft extenders and enhancers provides the foundation for most spinal fusions. ABG is the only graft option containing all 3 factors of new bone growth: osteoconductivity, osteoinductivity, and osteogenicity. While many bone graft alternatives function well as bone graft extenders, only growth factors proteins (ie, rhBMP-2 or OP-2) function as bone graft enhancers and substitutes. The search for optimal hybrid interbody cages, bone graft substitutes, autogenous or allogenic stem cells, and nanostructure scaffolds for release of growth factors continues.
S
pinal fusionsconstitute a large volume of spinal surgeries, estimated at 200 000 to 250 000 patients in the US annually, over a variety of indications including degenerative pathologies, deformity, trauma, and postdestructive processes (tumor, infection). [1] [2] [3] In addition, spinal arthrodesis procedures comprise the majority of bone graft procedures each year. 1 In order for fusion to take place, spinal segments are often immobilized with or without instrumentation, intervertebral devices, and/or bracing for transient stability from anterior, posterior, or lateral approaches. 4 Regardless of indication, a successful fusion is a biological process that depends on several factors and results in elimination of motion ABBREVIATIONS: ABG, autogenous bone graft; ACDF, anterior cervical discectomy and fusion; ACS, autologous conditioned serum; ALIF, anterior lumbar interbody fusion; BMA, bone marrow aspirate; BMP, bone morphogenic protein; DBM, demineralized bone matrix; HA, hydroxyapatite; ICBG, iliac crest bone graft; MSC, mesenchymal stem cells; PEEK, polyetheretherketone; PLIF, posterior lumbar interbody fusion; RCT, randomized controlled trial; TGF-b, transforming growth factorbeta; Ti, titanium; TLIF, transforaminal lumbar interbody fusion segments via bridging bone. Generally speaking the fusion depends on host bone exposure at the site of intended fusion and some combination of autograft, allograft, synthetics, stem cells, and/or growth factors. The choices are numerous, yet autologous bone remains the "gold standard" graft for spinal fusion. 5, 6 Autologous bone is most commonly harvested locally from the operative incision (ie, morselized spinous processes and laminae) or from the iliac crest (iliac crest bone graft, ICBG). Alternatives to autograft serve roles as graft extenders, enhancers, or substitutes. Identification of new osteobiologics will potentially allow for improvement in arthrodesis rates, pain reduction, and clinical outcomes that are cost-effective. Principles that guide selection of graft and the foundation of bony fusion are inclusion of all 3 of the following: osteoconductivity, osteoinductivity, and osteogenicity.
various host and graft factors from a local and system level. The first event of bone formation at an arthrodesis is the inflammatory phase, whereby a hematoma surrounds the arthrodesis site, inducing neovascularization and recruitment of osteogenic cells over the first 7 to 14 d. 7, 8 In the second phase, the reparative phase, the new bone is formed as the hematoma solidifies and bone graft is resorbed via endochondral and intramembranous bone fusion. 9 Membranous bone forms near the decorticated surfaces and endochondral ossification follows. 8 Vascularization occurs in the fibrovascular stroma. Osteoblast and chondroblast differentiation occurs, whereby osteoinduction takes place during week 4 to 5. 8 Slow ingrowth of bone into graft and substitution of graft by osteoclasts characterizes osteoconduction during this phase. 8 During the third and final phase, the remodeling phase, continued resorption of graft bone and organization of new bone occurs for 6 to 10 wk after initial insult. 8 Newly formed bone continues to mature according to Wolff 's law of bone formation, which states that bone with adapt to the mechanical loads under which it is placed. 10, 11 Therefore, compression at an arthrodesis site may actually stimulate healing such as in an anterior construct compared to a posterior construct where the graft is under tension. 10, 11 In this manner, interbody fusion was developed and popularized because of the increased surface area for fusion, mechanical load on the graft for promoting fusion, and relief of tension on posterior constructs. 12 The local fusion environment is an important step in initiating and supporting these events and deserves attention during the time of surgery. Various bony fusion environments exist included anterior column (interbody), intertransverse, and interlaminarfacet joint regions. Each of these regions varies in factors such as compression/load vs tension. 3 Bony surfaces (eg, lateral facet, pars interarticularis, transverse process) need to be maximally decorticated for delivery of blood supply, growth factors via marrow, and osteogenic cells. 3 In fact, primary blood supply originates from decorticated transverse processes. 3 In addition, reduced trauma to soft tissues in the local fusion environment may support neovascularization for the fusion mass.
The systemic fusion environment is additionally important. Systemic host factors such as nicotine, nutritional status, and pharmaceuticals affect bone formation. 10 Nonsteroidal antiinflammatory medications inhibit the inflammatory cascade which is integral to the first phase of bone formation and thereby have been shown to inhibit fusion. 13, 14 One study determined that a standard dose of dexamethasone (4 mg/kg/d) for 7 d decreased successful arthrodesis rate from 75% to 35% in rabbits. 3 Nicotine interferes with neovascularization and metabolism and leads to higher rates of pseudarthrosis. [15] [16] [17] [18] [19] In one rabbit study, it is estimated that even moderate nicotine exposure (1-2 packs per day) decreases the rate of successful arthrodesis from 56% to 0%. 3 The 3 principle cellular factors necessary for fusion to occur are osteoconductivity, osteoinductivity, and osteogenicity. An osteoconductive material must be present to serve as a scaffold for bony ingrowth and neovascularization to occur. Additionally, osteoconductive materials may be used to deliver bone growth factors, but do not formally contain growth factors such as BMP on their own. Osteoinductive factors or bone proteins/growth factors must be present to induce recruitment and differentiation of osteogenic cells. An osteoinductive substance must contain 1 or more growth factors. Osteogenic cells must be present to be induced to differentiate into osteoblasts, or osteoblast cells must be present at the fusion site from exposure and decortication of host bone. Autograft, in particular corticocancellous ICBG, is the only graft option that contains elements of all 3 cellular factors. Table 1 lists several categories of graft options and their properties related to fusion biology.
BASIC BONE GRAFT PRINCIPLES
Although autograft is the "gold standard," it is often in limited supply due to amount of bone harvested via required decompression or avoidance of additional incisions for harvest of ICBG due to donor site morbidity (prevalence reportedly as high as 30%) such as donor site pain, wound complications, and increased operative time. 3, 5, 6 For these reasons, use of ICBG has decreased over the past years, and the search for cost-effective alternative graft materials has increased to "extend" or "substitute" the effects of autograft. 20 Thereby numerous autograft alternatives are available and serve any one or combination of roles: extenders, enhancers, and substitutes. Some common options include allograft products (ie, corticocancellous chips, doweled bone, cortical fibers), recombinant growth factors, allogenic stem cells, and synthetic materials or ceramics.
Graft materials in relation to autograft can be thought of as extenders, enhancers, or substitutes. A bone graft extender allows the use of less autogenous bone graft (ABG) or allows a given amount of ABG to be stretched over a greater area with the same result. A bone graft enhancer is added to ABG to increase rate of successful fusion with same or less ABG. A bone graft substitute may be used in place of ABG with the same success rate. Currently, all available substitutes lack appropriate osteoconduction, osteoinduction, and osteogenicity on their own. 8 Ideally (1) ABG with or without extenders or enhancers or (2) ABG substitutes with or without extenders or enhancers can be assembled into various combinations with the goal of attaining all 3 principles of success bone fusion: osteoconductivity, osteoinductivity, and osteogenicity.
ALLOGRAFT OPTIONS
Allograft, or allogenic bone, is one of the most commonly used autograft alternatives for spinal fusions. 21 Allograft is obtained from cadavers and is readily available. Disadvantages include relatively slow incorporation into host bone, lacking vascularization, and lacking significant osteoinductive or osteogenic properties. 8 Choices of allograft include cortical, cancellous, or corticocancellous mixture; additionally, they can be morselized into chips, machines into fibers, or doweled into shapes as structural grafts. The indications for these options vary based on biology of bone formation. Cortical grafts serve as good structural grafts but are slower to incorporate bone and resorb. Use of these grafts includes single-or multilevel anterior cervical discectomy and fusions (ACDFs). In anterior cases, allograft can serve as an autograft extender or substitute. Cancellous grafts show excellent osteoconductivity but resorb more quickly and are not structural. Use of these grafts includes posterior spinal fusions. However, allograft alone placed into a fusion site under tension, typically cancellous, leads to lower rates of fusion than when combined with autograft. 22, 23 For this reason allograft typically serves as an autograft extender in posterior spinal fusions rather than substitute. One exception is posterior spinal fusions in pediatric populations, where allograft alone appears to result in similar fusion rates to those with autograft.
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Mineralized Allograft
Mineralized allograft is considered osteoconductive, only mildly osteoinductive, and nonosteogenic. 27 The processing for allograft is typically by lyophilization (freeze-drying) or by freezing (fresh frozen) to decrease antigenicity and eradicate infectious agents. Processing is responsible for decreasing the osteoinductivity and eliminating the osteogenicity seen in allografts.
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Demineralized Bone Matrix Allograft
In the 1990s, demineralized bone matrix (DBM) was introduced as another cadaveric allograft option. DBM is less osteoconductive than mineralized allograft and nonosteogenic, but main retain more osteoinductive properties. DBM is processed by removal of minerals by acid extraction (decalcified), leaving the extracellular matrix and a myriad of proteins and collagen, including variable amounts of bone morphogenic protein (BMP) and bone growth factors. 3, 29 The resulting extract is combined with carriers to form manufacturer-specific product (ie, putty, chips, gel, sheets, etc). 2 As mentioned, the osteoinductivity of DBM varies among products and manufacturers' formulations due to varied quantity of osteoinductive factors. 30, 31 One study demonstrated variable rates of BMP-2, -7, and -4 among different manufacturers and different batches from same manufacturer. 8 Due to potential osteoinductivity DBM may serve as an enhancer in addition to autograft extender. Cost for use in a 1-level fusion is estimated around $1100, but varies across institutions. 3 Current examples of DBM include Grafton (Osteotech, Eatontown, New Jersey), musculoskeletal transplant foundation (MTF; Synthes, West Chester, Pennsylvania), and AlloMatrix (Wright Medial, Memphis, Tennessee).
In initial studies of Grafton DBM (Osteotech Inc) a multicenter, prospective trial demonstrated equivalency of DBM plus local autograft in comparison to ICBG. 32 In this study one side of the instrumented posterolateral fusion was ICBG and the contralateral side was DBM plus autograft. Fusion rates at 2 yr for 120 patients were 52% in DBM/autograft and 54% for ICBG. 32 In a follow-up prospective, randomized controlled trial (RCT) in single-level posterior lumbar fusions, DBM/local autograft was compared to ICBG. 33 At 2 yr follow-up no significant difference was noted between groups (86% DBM vs 92% ICBG, P = .23). Another study investigated 1-and 2-level fusions utilizing DBM (Osteofil/ICM, Sofamor Dankek, Memphis, Tennessee) and local autograft. 34 Rates of fusion at 1-and 2-yr follow-up were 98% and 96%, respectively. 34 Clearly, data supports the use of DBM as an autograft extender in posterior spinal fusions. Data are limited on the use of DBM in anterior spinal fusions.
SYNTHETICS
Synthetics provide yet another alternative to autograft for spinal fusions, primarily serving a role as an osteoconductive scaffold. Ceramics are neither osteoinductive or osteogenic. In this manner, synthetics merely serve as bone graft extenders and must be used with autograft or materials that provide osteoinductive and osteogenic potential. 3 Examples of more commonly used synthetics include beta-tricalcium phosphate, hydroxyapatite (HA), and calcium sulfate; their use is most often applied in posterolateral spinal fusions.
The major disadvantage of ceramics is that they are weak and brittle and have increased resorption rates. Their use is limited in the anterior spine because of the need to shield them from significant compressive forces. Additionally, they are subject to the same disadvantages as allograft in posterior fusions under tension. 35, 36 Synthetics have been modified to hybrid materials in the attempt to impart osteoinductive and osteogenic properties. For example, DBM, growth factors, or ions (silicate, magnesium) can be combined with ceramic graft to increase bone formation. [37] [38] [39] Research into synthetics as potential ABG substitutes has increased due to ability to manipulate microscopic and structural properties of these materials.
INTERBODY CAGES
The design of intervertebral cages has undergone a dramatic evolution over the past 30 yr from stainless steel to 3-dimensional (3D) printed titanium (Ti) cages and expandable Ti cages. The initial presentation of cage technology was in 1988 with stainless steel Bagby cage in the cervical and lumbar spine. 40 Since the initial development of cages, the most common materials include polyetheretherketone (PEEK), Ti, and carbon fiber-reinforced polymers. Other recent advancements include development of the interface with surface processing or application of additional materials with primary goal of improving fusion rates.
Polyetheretherketone
PEEK synthetic cages provide excellent biomechanical strength, yet fusion is typically dependent upon the addition of other osteoconductive or osteoinductive agents. First developed in 1978, PEEK is semicrystalline, thermoplastic, and highly wear resistant. 41 Compared to Ti, PEEK has a lower modulus of elasticity which decreases stress shielding and has the advantage of being radiolucent to assess osseointegration. Additionally, it is hydrophobic and has a limited ability for cells to bond and thus predisposes to a thin layer of fibrous tissue surrounding the implant rather than direct integration with bone. 42 This interaction is known as the PEEK-halo effect radiologically and has been well described. 43 Additionally this layer of fibrous tissue at the interface may precipitate micromotion and nonunion. Because of the ideal biomechanical characteristics but suboptimal interface characteristics, design has been directed towards improving bioactivity and osseointegration while maintaining the radiolucency and biomechanics. These developments include creating hybrid composites of PEEK with Ti, HA, calcium silicate, carbon fiber, or beta-tricalcium phosphate.
Titanium
Ti in addition to being used as a component of hybrid implants is used as a standalone implant. Since 1980 Ti has been used for its low density, biomechanical strength, biocompatibility, and high corrosion resistance. Compared to PEEK and host bone, Ti has a higher modulus of elasticity which increases stress shielding and potential subsidence. Its 3D implant conformation can be varied to a range of porosity up to 60% to 70%. 44 Ti can undergo surface roughness modification with plasma spray, electron beam melting, or 3-D printing or with chemical coating which can render them bioactive and improve osseointegration via improved bone-on growth, apposition of bone to surface of the implant (bone-implant contact), and bone ingrowth on roughened surface compared to smooth. [45] [46] [47] [48] Other modifications include HA coating, removal of sodium ions, alkali treatment, and heat treatment; furthermore nanoparticles can be added such as Ti oxide (TiO 2 ) and zirconia (ZrO 2 ). Treatments to microroughness and nanostructure of the implant can be synergistic with other treatments. 46 Long-term clinical data with bioactive Ti implants have not yet been published.
Alternative Metals
Tantalum is a porous metal with open-cell structure resembling cancellous bone with a porosity between 75% and 85%. It has a low modulus of elasticity similar to endochondral bone and one of the highest coefficients of friction. 49 The porous structure encourages bony integration, remodeling, and vascularlization. 50 Tantalum, however, is biologically inert and has limited direct bonding to bone. Clinical studies in humans demonstrated lower fusion rates than standard grafts. For example, in a study of ACDFs randomized to tantalum ring with autograft, tantalum alone, or ICBG, fusion rates at 24 mo were 44% vs 100%; furthermore, other studies recapitulated concern regarding lower fusion rates with tantalum. [51] [52] [53] Despite some studies reporting higher fusion rates in anterior, posterior, and transforaminal lumbar fusions, subsidence is a clear concern with tantalum. 54, 55 Silicon nitride (Si 3 N 4 ) is a ceramic material with similar strength and compression to PEEK and Ti. 56 Silicon nitride has a hydrophilic, negatively charged surface that facilitates osseointegration by increasing adhesion of cells and proteins. 57 This unique material has an ability to decrease bacterial biofilm formation in comparison to PEEK and Ti. 58 RCTs comparing silicon nitride to PEEK grafts are ongoing in ACDF and TLIF settings.
56,59
Hybrid
As discussed above, hybrid composites have been developed with PEEK implants. Ti-PEEK hybrids can be made via Ti endplates compressed onto a PEEK core; coating via plasma spray, direct metal laser sintering, or electron beam deposition; or compression molding. Concern exists regarding the surface material-implant interface (ie, Ti endplate-PEEK interface) such as delamination during insertion or micromotion after implantation. 60 Despite these concerns, bioactivity of PEEK has been shown to be increased in preclinical and in vivo studies. [61] [62] [63] These improved qualities include improved overall osseointegration via cell attachment, increased bone deposition and remodeling; improved cell survival and higher alkaline phosphatase activity; less fibrous tissue encapsulation; and greater pull-out and push-out strength. [61] [62] [63] Hybrids have also been developed with HA-PEEK. HA can be applied via aerosol deposition, plasma spray, or cold spray. The bioactivity of PEEK has been shown to be improved in preclinical and in vivo animal studies including improved cell survival and attachment, cell proliferation, higher alkaline phosphatase activity, greater bone-implant-contact, and increased removal torque. [64] [65] [66] [67] However, no published clinical results currently exist for HA-PEEK use in human spine surgery.
OSTEOINDUCTIVE FACTORS
Spinal osteobiologics, various proteins, factors, and stem cells, are increasingly becoming utilized in spinal arthrodesis and have evolved substantially in the last several decades. Various osteoinductive factors have been discovered and are currently being utilized in spinal applications as autograft enhancers. These factors include recombinant human (rh) BMP-2, BMP-7 (osteogenic protein-1, or OP-1), and autologous growth factor concentrate.
Bone Morphogenic Protein
Bone morphogenic proteins are a soluble member of the transforming growth factor-beta (TGF-b) superfamily and were first discovered by Urist and colleagues in the 1960s. [68] [69] [70] [71] [72] These proteins are osteoinductive by inducing pluripotent mesenchymal stem cells (MSC) to become osteoblasts. 5 BMPs interact with serine-threonine kinase receptors and transduce intracellular signals through the SMAD cascade, ultimately resulting in expression of target genes leading to osteogenesis. BMPs are the only growth factors utilized that induce the entire process of bone formation de novo. 3 Several clinical studies have examined the efficacy of rhBMPs. [73] [74] [75] With scientific advances BMP can now be produced with recombinant gene technology for clinical use. BMP's initial indication, anterior lumbar interbody fusion (ALIF), was studied in a 279-patient multicenter, prospective RCT with interbody cage (LT-CAGE, Medtronic, Dublin, Ireland) filled with rhBMP-2 sponge or ICBG. 73 Fusion rates were 94.5% for rhBMP-2 and 88.7% for ICBG at 24 mo, confirming BMP use as a bone graft substitute in this indication (ALIF). 73 Following this and early clinical studies, rhBMP-2 (INFUSE, Medtronic) was approved for single-level interbody fusion in the lumbar spine from L4 to S1 in 2002.
Following initial success of BMP use in ALIF cases, BMP has been studied in other indications in RCTs and case studies as well as being used in off-label indications based on data indicating equivalent or superior efficacy to ICBG. 73, 76, 77 The use of BMP is estimated to have increased from 1116 cases in 2002 to nearly 79 294 cases by 2011. 5, 78 One such indication studied was posterolateral fusions utilizing rhBMP-2 at a higher dose. In this study, ICBG was compared to rhBMP-2 matrix comprised of type I bovine collagen with 15% HA and 85% beta-tricalcium phosphate. 79 Four hundred sixty-three patients underwent singlelevel posterior lumbar fusion for degeneration, and fusion rates were increased at 24 mo to 96% compared to 89% for ICBG group. 79 However, due to concerns and unclear data regarding cancer risk, the FDA rejected rhBMP-2 use at higher dose.
Another indication studied included posterior lumbar interbody fusion (PLIF) and transforaminal lumbar interbody fusion (TLIF). In a retrospective study, rhBMP-2 was compared to local autograft in one-or two-level PLIF or TLIF. 80 Results, however, were mixed demonstrating statistically insignificant rates of fusion between groups (94.1% for rhBMP-2 and 89.5% for autograft, P = .61) and a higher rate of complications in the rhBMP-2 group (41.2% compared to 10.5%) which included radiculitis, ectopic bone formation, and vertebral osteolysis. 80 As data amassed from industry-sponsored studies, some authors began to look at aggregate data for outcomes and complications. At the same time, postoperative adverse events attributable to rhBMP-2 were being reporting and clinical usage declined. 81 Complications being reported in the literature included radiculitis, osteolysis, heterotopic ossification, retrograde ejaculation, seroma/hematoma, prevertebral swelling, and increased rates of new malignancy.
5,82-85 Carragee et al 83 reviewed 13 industry trials with a total of 780 patients treated with rhBMP-2. In total they found that rhBMP-2 was associated with adverse events in 10% to 50% of cases. In particular, ALIFs with BMP were associated with higher rates of retrograde ejaculation, infection, urogenital events, and implant failure. PLIFs were associated with ectopic bone, osteolysis, and radiculitis. 83 Due to the clear contrast of these results with initial studies, use of and knowledge of BMP-associated outcomes became the subject of ongoing research. Medtronic submitted all available INFUSE data in 2011: independent review of industry-sponsored data was then done as part of the "Yale Open Data Access Project." Ultimately, the review demonstrated no significant difference in outcomes with rhBMP-2 (INFUSE) compared to ICBG, and high fusion rates were seen, in particular for ALIF and PLIF cases. [86] [87] [88] However, complications were higher, particularly when used for anterior cervical spinal fusions. The data examined however were from many small sample size and nonrandomized trials which makes interpretation difficult. 86, 87 Additionally, the research groups differed in conclusions regarding associated cancer risk, although absolute risk remained low compared to the general population. A systematic review published in 2015 of all available basic science literature did not find evidence of rhBMP-2 causing cancer de novo. 89 Another osteoinductive protein, initially discovered in the 1980s, is BMP-7, also known as osteogenic protein-1 (OP-1). In 2004 OP-1 was approved for revision posterior lumbar spinal fusions under human device exemption, however an early clinical trial failed to show noninferiority. [90] [91] [92] [93] [94] [95] [96] [97] Autologous Growth Factor Concentrate (Platelet Ultrafiltrate)
In the search for cost-effective bone growth factors, the process of autologous conditioned serum (ACS) has been developed by extracting, modifying, and reintroducing a patient's concentrated serum for a variety of conditions. 98-100 Degranulation of platelets has been shown to release a variety of growth factors such as platelet derived growth factor (PDGF) and TGF-beta. ACS or autologous growth factor concentrate may enhance new bone formation in lumbar spinal fusions. However, several studies have evaluated autograft plus ACS in posterior spinal fusions and ACS in TLIF and found that it did not enhance fusion rates. 
Growth Factor Carriers
In addition to research and development of growth factors themselves, much development has been done in carrier technology for proper delivery and release of growth factors to the local environment for fusion. Carriers restrict movement of factors and cells and allow for timed released. Examples of carriers include ABG, ceramics, collagen, DBM, and poly-L-lactic acid. 101, 102 Limited ability of carriers to properly bind and release factors such as rhBMP-2 may lead to burst release of factors and adverse events such as seroma/hematoma and ectopic bone. [103] [104] [105] Time dependent release of growth factors is potentially important as research has shown BMP-2 mRNA expression to increase week 2 through 6, with peak expression in weeks 3 and 4 (40-fold increase).
3 Development in this arena has led to production of nanostructure biomaterials such as bioabsorbable collagen scaffold with nanofibers to bind growth factors. Nanoscale materials provide molecular interactions between growth factors, cells and scaffold materials.
Biomimetic scaffolds are similarly utilized to imitate the natural elements of bony fusion in order to be biocompatible with specific cell types. 8 One example is heparin sulfate incorporated into a scaffold, enhancing rhBMP-2 retention for enhancing bone formation and preventing supraphysiological doses of rhBMP-2. 105 Another example of a biomimetic is P-15 which is a 15-amino acid peptide that resembles a part of collagen, approximating the physiological environment in which bone healing occurs.
CELL-BASED THERAPIES/STEM CELLS
The use of osteogenic stem cells is rapidly expanding and being investigated for their potential to enhance bony fusion. MSCs are pluripotent cells that possess the ability to differentiate into osteoblasts in the proper growth factor milieu. 5 These stem cells are found in bone marrow, adipose tissue, muscle, and periosteum.
Autologous Stem Cells
Autologous bone marrow aspirate (BMA) is one potential source of osteoinductive factors and osteogenic cells. BMA can be obtained from the vertebral body pedicles during aspiration or via percutaneous aspiration in the iliac crest, and concentration of osteogenic progenitor cells varies on harvest location. Vertebral pedicles have 71% greater concentration than iliac crest of osteogenic progenitor cells. 106, 107 BMA added to an osteoconductive matrix potentially contains all 3 components of bone graft. The major limitation to BMA is that unfractionated, whole marrow has moderate osteogenic potential: a low concentration of MSCs is found at 1 in 10 000 to 50 000 cells and varies depending on patient age and metabolic disorders such as osteoporosis. 5 Several studies have attempted to increase the yield of MSC harvesting via selectively retaining MSCs or ex vivo expansion of these cells in culture before transferring them to an osteoconductive matrix. 108 Unfortunately, these processes prove inefficient, costly, and problematic with sterility in the human scenario, where cells are needed at time of surgery to add into bone graft. One promising possibility is centrifugation of BMA at the time of surgery.
Initial rabbit and primate animal studies demonstrated efficacy in spinal fusion. 106, 109 In one animal study, BMA used as bone graft extender/enhancer significantly increased rates of arthrodesis in a rabbit model. 108 One study utilized autologous MSCs from the iliac crest with porous tricalcium phosphate for posterior spinal fusions with fusion rate of 95.1%. 110 In another retrospective study of revision fusions, 62 patients received either rhBMP-2, BMA with DBM, or autograft. 111 In this study rhBMP-2 and BMA/DBM groups had equivalent, 100% arthrodesis rates in single-level fusions; however, in multilevel fusions, BMA had a 63.6% fusion rate compared to 100% in rhBMP-2 and autograft. 111 In a recent human, prospective RCT, 24 patients underwent one-to three-level posterior lumbar fusions with either BMA plus allograft or ICBG on opposite sides of the level of arthrodesis. 112 Results demonstrated no difference in rate of fusion between "gold standard" ICBG and BMA/allograft in the lumbar spine.
Allogeneic Stem Cell Products
For reasons of donor site morbidity or procedural time, allogenic MSC-derived products exist for clinical use. These products significantly vary in regard to total MSC concentration, donor age, shelf life, and cell viability. Study outcomes are inconclusive with allogenic MSCs. For example, in a nonindustry 1-or 2-level ACDF study comparing Osteocel (NuVasive, San Diego, California) with structural allograft, fusion rates were found to be 87.7% compared to 94.7% (P = .17). 113 Significant research remains and is ongoing utilizing MSC alternatives to determine outcomes and cost-effectiveness. Additionally, these products are traditionally regulated through the human cellular tissue product pathway, so little efficacy data are typically required before commercialization of products.
CONCLUSION
Many promising technologies are currently in use or under development for improving the outcomes of spinal fusions. However, proper guidance with knowledge of mechanisms of action and rigorous clinical trials is paramount to help guide practitioners on the selection of autograft extenders, enhancers, and/or substitutes to incorporate all three factors of bony fusion to obtain the optimal clinical result for patients. Continued research is necessary for cost-effective and efficacious treatment modalities for the spinal fusion patient population.
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